🇺🇸 FDA
Pipeline program

Intensity-modulated radiotherapy

2017-FXY-055-NPC

Unknown other active

Quick answer

Intensity-modulated radiotherapy for Nasopharyngeal Carcinoma is a Unknown program (other) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Nasopharyngeal Carcinoma
Phase
Unknown
Modality
other
Status
active

Clinical trials